Who are AS (Guilin Pharmaceuticals)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Artesunate (Comparator), artesunate (AS), artesunate sachets, artesunate-amodiaquine (AS-AQ), Artesunate 2, Artemether Sublingual Spray.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/as-guilin-pharmaceuticals.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AS (Guilin Pharmaceuticals) — Competitive Intelligence Brief

AS (Guilin Pharmaceuticals) (AS (Guilin Pharmaceuticals)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artemisinin derivative. Area: Infectious Disease.

phase 3 Artemisinin derivative Plasmodium heme-dependent activation Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

AS (Guilin Pharmaceuticals) (AS (Guilin Pharmaceuticals)) — London School of Hygiene and Tropical Medicine. AS is an artemisinin-based antimalarial compound that generates reactive oxygen species to kill malaria parasites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AS (Guilin Pharmaceuticals) TARGET	AS (Guilin Pharmaceuticals)	London School of Hygiene and Tropical Medicine	phase 3	Artemisinin derivative	Plasmodium heme-dependent activation
Artesunate (Comparator)	Artesunate (Comparator)	Pfizer	marketed	Artemisinin derivative	Parasite proteins (non-specific alkylation via reactive oxygen species)
artesunate (AS)	artesunate (AS)	London School of Hygiene and Tropical Medicine	marketed	Artemisinin derivative	Plasmodium heme and iron-dependent mechanisms
artesunate sachets	artesunate sachets	Pfizer	marketed	Artemisinin derivative	Plasmodium parasites (multiple targets including heme and parasite proteins)
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
Artesunate 2	Artesunate 2	University of Oxford	marketed	Artemisinin derivative	Malaria parasite heme; potential cancer cell apoptosis pathways
Artemether Sublingual Spray	Artemether Sublingual Spray	Proto Pharma Ltd	phase 3	Artemisinin derivative	Heme iron (parasite-derived); multiple parasite proteins and membranes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artemisinin derivative class)

London School of Hygiene and Tropical Medicine · 2 drugs in this class
Pfizer · 2 drugs in this class
Proto Pharma Ltd · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AS (Guilin Pharmaceuticals) — Competitive Intelligence Brief. https://druglandscape.com/ci/as-guilin-pharmaceuticals. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab